Ph.D. William Benton Jones - 04 Dec 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: SVP, Pharmaceutical Development
Issuer ticker: CRVS
Reported as of: 04 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Dec 2025, 16:23:09 UTC
Prior SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Leiv Lea, as Attorney-in-Fact for William Benton Jones, Ph.D.

Key filing fact

Ph.D. William Benton Jones filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 08 Dec 2025.

Key facts

This page summarizes Ph.D. William Benton Jones's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Dec 2025, 16:23.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001664506 Primary reporting owner

Jones William Benton

Relationship: SVP, Pharmaceutical Development
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Leiv Lea, as Attorney-in-Fact for William Benton Jones, Ph.D.
Signature date: 08 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +400,000
Change %
Price: $0.000000
Shares after: 400,000
Date: 04 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $8.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC remarks

SVP, Pharmaceutical Development